Home
Suven Life Sciences Limited
Press Release Dec 11 2025
Business
Dec 11 2025
5 min read

Press Release Dec 11 2025

Suven Life Sciences Limited has informed the Exchange regarding a press release dated December 11, 2025, titled "Suven Life Sciences achieved 100% Patient Enrolment Milestone in Phase-2b Clinical Trial of Ropanicant for Major Depressive Disorder (MDD), more than Two Months Ahead of Schedule".

View Attachment

Oorspronkelijke tekst
Deze vertaling beoordelen
Je feedback wordt gebruikt om Google Translate te verbeteren